United States Insulin Delivery Devices Market Report 2021

The United States Insulin Delivery Devices Market is expected to surpass US$ 10 billion by 2027.

The “United States Insulin Delivery Devices Market Size, Analysis, Insights, Trends, Share Outlook, Opportunities, Companies and Forecasts up to 2027” report has been added to ResearchAndMarkets.com’s offering.

The United States Insulin Delivery Devices Market is expected to surpass US$ 10 billion by 2027.

This new report provides an in-depth assessment of the U.S insulin delivery devices market dynamics, opportunities, future road-map, competitive landscape and discusses major trends. The report presents the most up-to-date industry data on the actual and potential market situation and future outlook for insulin delivery devices in the United States.

The report also provides up-to-date historical market size data for the period 2019 – 2020 and an illustrative forecast to 2027 covering key market aspects like market value and volume for insulin delivery devices in the United States.

The United States insulin delivery devices market is one of the high-growth evolving industries with potential opportunities throughout 2027. The report delivers an all-around analysis of the overall number of patients with diabetes in the United States. Moreover, the report provides deep insights on type 1, type 2, and newly diagnosed type 1 diabetes patients’ data.

Additionally, this report provides overall insulin delivery devices users’ insights and up-to-date market size with more focus on their product categories such as Insulin Pump, Insulin Pen, Insulin Syringe, Insulin Inhaler, and Insulin Jet Injector.

Additionally, this up-to-date market report describes the latest features reimbursement pattern and offers a clear view of the regulatory framework of the United States insulin delivery devices market. Key trends in terms of collaboration, partnership deals, licensing, and exclusive agreement are analyzed in detail. The report also delivers an in-depth analysis of evolving market trends, drivers, and restraining forces that influence the growth of the U.S insulin delivery devices market.

The report also analyses detailed profiles of innovative and leading players with information on business overview, product portfolio, and the latest developments.

Key Questions Addressed by the Report:

  • What is the current size of the overall insulin delivery devices market in the United States?
  • How much will this market be worth from 2021 to 2027?
  • How big is the United States insulin delivery devices market?
  • What is the total insulin delivery devices users volume in the United States?
  • What are the key marketed insulin delivery devices available in the United States?
  • What are the major drivers of the United States insulin delivery devices market?
  • What are the major inhibitors of the United States insulin delivery devices market?
  • What is the reimbursement pattern of the United States insulin delivery devices market?
  • What is the regulatory framework of the United States insulin delivery devices market?
  • Which companies make insulin delivery devices?
  • Who are the top market players? What are their happenings, current developments, and scenarios?

The Leading Companies for the United States Insulin Delivery Devices Market are Listed Below:

  • Medtronic
  • Tandem Diabetes Care
  • Insulet Corporation
  • Sooil Development
  • Novo Nordisk
  • Eli Lilly and Company
  • Sanofi
  • Owen Mumford
  • Companion Medical
  • Diabnext
  • Digital Medics Pty Ltd.
  • Emperra GmbH E-Health Technologies
  • Diamesco Co., Ltd.
  • Becton, Dickinson, and Company (BD)
  • Abbott Diabetes Care
  • Smith’s Medical, Inc.
  • Arkray, Inc
  • Trividia Health, Inc
  • MHC Medical Products, LLC
  • Home Aide Diagnostics, Inc
  • Advocate Meters (Pharma Supply, Inc.)
  • Retractable Technologies, Inc.
  • Prodigy Diabetes Care, LLC
  • UltiMed, Inc
  • AdvaCare Pharma USA, LLC
  • Allison Medical, Inc
  • Cardinal Health, Inc
  • MannKind Corporation
  • Insujet

Key Topics Covered:

1. Executive Summary

2. United States Diabetes Population (2019 – 2027): An Analysis
2.1 Overall Diabetes Population
2.1.1 Type 1 Diabetes
2.1.2 Type 2 Diabetes
2.1.3 Newly Diagnosed Type 1 Diabetes

3. United States Insulin Delivery Devices Users Analysis (2019 – 2027)
3.1 Overall Insulin Delivery Users Snapshot
3.2 Insulin Pump Users
3.2.1 Type 1 Diabetes Insulin Pump Users
3.2.2 Type 2 Diabetes Insulin Pump Users
3.3 Insulin Pen Users
3.3.1 Reusable (Cartridge) Insulin Pen Users
3.3.2 Prefilled (Disposable) Insulin Pen Users
3.3.3 Smart Insulin Pen Users
3.4 Insulin Pen Segment – (Reusable, Prefilled, Smart Insulin Pen) Users Share
3.5 Insulin Syringe Users
3.6 Insulin Inhaler Users
3.7 Insulin Jet Injector Users

4. United States Insulin Delivery Devices Market Size and Forecast (2019 – 2027)
4.1 Overall Insulin Delivery Devices Market Snapshot
4.2 Insulin Delivery Devices Segment – (Insulin Pump, Insulin Pen, Insulin Syringe, Insulin Inhaler, Insulin Jet Injector) Market Share
4.3 Insulin Pump Market Size
4.4 Insulin Pen Market Size
4.4.1 Reusable (Cartridge) Insulin Pen Market
4.4.2 Prefilled (Disposable) Insulin Pen Market
4.4.3 Smart Insulin Pen Market
4.5 Insulin Pen Segment – (Reusable, Prefilled and Smart Insulin Pen) Market Share
4.6 Insulin Syringe Market Size
4.7 Insulin Inhaler Market Size
4.8 Insulin Jet Injector Market Size

5. Key Market Growth Drivers and Challenges of the United States Insulin Delivery Devices Market
5.1 Market Growth Drivers
5.2 Market Challenges

6. Regulatory Framework of the United States Insulin Delivery Devices Market

7. Reimbursement Environment of the United States Insulin Delivery Devices Market
7.1 Insulin Pump
7.2 Insulin Pen
7.3 Insulin Syringe
7.4 Insulin Inhaler
7.5 Insulin Jet Injector

8. Major Deals Happening in the Insulin Delivery Devices Market
8.1 Collaboration Deals
8.2 Licensing Agreement
8.3 Exclusive Agreement
8.4 Partnerships Deal

9. Key Companies Analysis
9.1 Business Overview
9.2 Product Portfolios
9.3 Latest Development

For more information about this report visit here.

Hot this week

Cartessa Aesthetics Partners with Classys to Bring EVERESSE to the U.S. Market

Classys, which is listed on the KOSDAQ, is one of South Korea's most distinguished aesthetic technology manufacturers, with devices distributed in 80+ markets globally. This partnership marks Classys's official entry into the American marketplace, with Cartessa Aesthetics as the exclusive distributor for EVERESSE, launched under the Volnewmer brand in current global markets.

Stryker Launches Next-Generation of SurgiCount+

Now integrated with Stryker's Triton technology, SurgiCount+ addresses two key challenges: retained surgical sponges and blood loss assessment. Integrating these previously separate digital solutions provides the added benefit of a more efficient, streamlined workflow for hospitals notes Stryker.

Nevro Receives CE Mark In Europe for It’s HFX iQ™ Spinal Cord Stimulation System

Nevro notes HFX iQ is the first and only SCS system with artificial intelligence (AI) technology that combines high-frequency (10 kHz) therapy built on landmark evidence that uses ongoing cloud data insights to deliver personalized pain relief

Recor Medical Reports: CMS Grants Distinct TPT Device Code and Category to Recor Medical for Ultrasound Renal Denervation

The approval of TPT offers incremental reimbursement payments for outpatient procedures performed with ultrasound renal denervation for Medicare fee-for-service beneficiaries. It becomes effective January 1, 2025, and is expected to remain effective for up to three years notes Recor Medical.

Jupiter Endovascular Reports | 1st U.S. Patient Treated with Jupiter Shape-shifting Thrombectomy Device

“Navigation challenges during endovascular procedures are often underappreciated and have led to under-adoption of life-saving procedures, such as pulmonary embolectomy. We have purpose-built our Endoportal Control technology to solve these issues and make important endovascular procedures accessible to more clinicians and their patients who can benefit from them,” said Carl J. St. Bernard, Jupiter Endovascular CEO. “This first case in the U.S. could not have gone better, and appears to validate the safety and performance we are seeing in our currently-enrolling European SPIRARE I study.”
Exit mobile version